Drugs / OTQ923
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06155500 | Apr 2024 → Jan 2039 expected | sickle cell disease | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04443907 | Aug 2020 → Jan 2025 | sickle cell disease | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-03-31 | Intellia Therapeutics | Regulatory FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics intelliatx.com ↗
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-03-31 | Intellia Therapeutics | FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics intelliatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTQ923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04443907 ↗ |
| Route | Intravenous | “Single intravenous infusion of OTQ923 cell suspension” NCT04443907 ↗ |